Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003478 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00003478 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 10 participants.
The verdict
NCT00003478, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: This randomized phase I/II trial is studying the side effects, best way to give, and best dose of radiolabeled monoclonal antibody and to see how well it works in treating patients with primary brain tumors.
Interventions
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- RADIATION iodine I 131 monoclonal antibody 81C6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1997-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003478
The ClinicalTrials.gov registry entry for NCT00003478 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which conventional surgery is the first listed.
NCT00003478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003478 about?
NCT00003478 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors". RATIONALE: Monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: This randomized phase I/II trial is studying the side effects, best way to give, and best dose of radiolabeled monoclona...
What is the current status of trial NCT00003478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 1997-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00003478?
The interventions under investigation include: conventional surgery (PROCEDURE), radiation therapy (RADIATION), iodine I 131 monoclonal antibody 81C6 (RADIATION).
Who is sponsoring clinical trial NCT00003478?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.